The safety and efficacy of intrathecal delivery of AAV vectors targeting mutant SOD1 have also been demonstrated in non-human primate models41,44 and more recently in two familial ALS patients carrying SOD1 gene mutations45. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.